Amgen Inc. Common Stock and Additional Paid-In Capital
Amgen Inc. (AMGN) had Common Stock and Additional Paid-In Capital of $34.08 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:CommonStocksIncludingAdditionalPaidInCapital · last filed 2026-08-05
- 2026-06-30: Common Stocks, Including Additional Paid in Capital $34.08B.
- 2026-03-31: Common Stocks, Including Additional Paid in Capital $34.03B.
- 2025-12-31: Common Stocks, Including Additional Paid in Capital $34.02B.
- 2025-09-30: Common Stocks, Including Additional Paid in Capital $33.84B.
| Period end | Common Stocks, Including Additional Paid in Capital |
|---|---|
| 2026-06-30 | $34.08B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $34.03B 10-Q · filed 2026-05-01 |
| 2025-12-31 | $34.02B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $33.84B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $33.68B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $33.58B 10-Q · filed 2025-05-02 |
| 2024-12-31 | $33.53B 10-K · filed 2026-02-13 |
| 2024-09-30 | $33.39B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $33.20B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $33.08B 10-Q · filed 2024-05-03 |
| 2023-12-31 | $33.07B 10-K · filed 2025-02-14 |
| 2023-09-30 | $32.75B 10-Q · filed 2023-10-31 |
| 2023-06-30 | $32.60B 10-Q · filed 2023-08-04 |
| 2023-03-31 | $32.53B 10-Q · filed 2023-04-28 |
| 2022-12-31 | $32.51B 10-K · filed 2024-02-14 |
| 2022-09-30 | $32.37B 10-Q · filed 2022-11-04 |
| 2022-06-30 | $31.34B 10-Q · filed 2022-08-05 |
| 2022-03-31 | $31.25B 10-Q · filed 2022-04-28 |
| 2021-12-31 | $32.10B 10-K · filed 2023-02-09 |
| 2021-09-30 | $31.99B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $31.88B 10-Q · filed 2021-08-04 |
| 2021-03-31 | $31.81B 10-Q · filed 2021-04-28 |
| 2020-12-31 | $31.80B 10-K · filed 2022-02-16 |
| 2020-09-30 | $31.71B 10-Q · filed 2020-10-29 |
| 2020-06-30 | $31.61B 10-Q · filed 2020-07-29 |
| 2020-03-31 | $31.52B 10-Q · filed 2020-05-01 |
| 2019-12-31 | $31.53B 10-K · filed 2021-02-09 |
| 2019-09-30 | $31.45B 10-Q · filed 2019-10-30 |
| 2019-06-30 | $31.31B 10-Q · filed 2019-07-31 |
| 2019-03-31 | $31.24B 10-Q · filed 2019-05-01 |
| 2018-12-31 | $31.25B 10-K · filed 2020-02-12 |
| 2018-09-30 | $31.14B 10-Q · filed 2018-10-31 |
| 2018-06-30 | $31.05B 10-Q · filed 2018-07-27 |
| 2018-03-31 | $31.00B 10-Q · filed 2018-04-25 |
| 2017-12-31 | $30.99B 10-K · filed 2019-02-13 |
| 2017-09-30 | $30.90B 10-Q · filed 2017-10-26 |
| 2017-06-30 | $30.79B 10-Q · filed 2017-07-26 |
| 2017-03-31 | $30.77B 10-Q · filed 2017-04-27 |
| 2016-12-31 | $30.78B 10-K · filed 2018-02-13 |
| 2016-09-30 | $30.69B 10-Q · filed 2016-10-28 |
| 2016-06-30 | $30.59B 10-Q · filed 2016-07-29 |
| 2016-03-31 | $30.59B 10-Q · filed 2016-05-02 |
| 2015-12-31 | $30.65B 10-K · filed 2017-02-14 |
| 2015-09-30 | $30.56B 10-Q · filed 2015-11-02 |
| 2015-06-30 | $30.46B 10-Q · filed 2015-08-05 |
| 2015-03-31 | $30.42B 10-Q · filed 2015-04-27 |
| 2014-12-31 | $30.41B 8-K · filed 2016-10-31 |
| 2014-09-30 | $30.13B 10-Q · filed 2014-10-29 |
| 2014-06-30 | $29.98B 10-Q · filed 2014-08-05 |
| 2014-03-31 | $29.89B 10-Q · filed 2014-04-30 |
| 2013-12-31 | $29.89B 10-K · filed 2015-02-19 |
| 2013-09-30 | $29.66B 10-Q · filed 2013-10-29 |
| 2013-06-30 | $29.52B 10-Q · filed 2013-08-06 |
| 2012-12-31 | $29.34B 10-K · filed 2014-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |